Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Mitogen Activated Protein Kise Kise Kise 5 (Apoptosis Sigl Regulating Kise 1 or MAPK/ERK Kise Kise 5 or MAP3K5 or EC 2.7.11.25) - Overview
Mitogen Activated Protein Kise Kise Kise 5 (Apoptosis Sigl Regulating Kise 1 or MAPK/ERK Kise Kise 5 or MAP3K5 or EC 2.7.11.25) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Mitogen Activated Protein Kise Kise Kise 5 (Apoptosis Sigl Regulating Kise 1 or MAPK/ERK Kise Kise 5 or MAP3K5 or EC 2.7.11.25) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Mitogen Activated Protein Kise Kise Kise 5 (Apoptosis Sigl Regulating Kise 1 or MAPK/ERK Kise Kise 5 or MAP3K5 or EC 2.7.11.25) - Companies Involved in Therapeutics Development
Angion Biomedica Corp
Calchan Ltd
Chipscreen Biosciences Ltd
Enta Pharmaceuticals Inc
FronThera US Pharmaceuticals LLC
Gilead Sciences Inc
Kyowa Kirin Co Ltd
Seal Rock Therapeutics Inc
Takeda Pharmaceutical Co Ltd
Terns Pharmaceuticals Inc
Mitogen Activated Protein Kise Kise Kise 5 (Apoptosis Sigl Regulating Kise 1 or MAPK/ERK Kise Kise 5 or MAP3K5 or EC 2.7.11.25) - Drug Profiles
ANG-4102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CS-410 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EP-026856 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EP-027315 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GLPG-3535 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GS-444217 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GS-459679 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
selonsertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit ASK-1 for Chronic Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit ASK1 for Non-Alcoholic Steatohepatitis and Non-Alcoholic Fatty Liver Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit ASK1 for Thrombosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Fibrosis, Hematological Diseases and Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Apoptosis Sigl-Regulating Kise 1 for Unspecified Indication - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit ASK1 for Amyotropic Lateral Sclerosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit ASK1 for Myocardial Infarction, Neurodegenerative Diseases and Rheumatoid Arthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRT-015 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Mitogen Activated Protein Kise Kise Kise 5 (Apoptosis Sigl Regulating Kise 1 or MAPK/ERK Kise Kise 5 or MAP3K5 or EC 2.7.11.25) - Dormant Products
Mitogen Activated Protein Kise Kise Kise 5 (Apoptosis Sigl Regulating Kise 1 or MAPK/ERK Kise Kise 5 or MAP3K5 or EC 2.7.11.25) - Discontinued Products
Mitogen Activated Protein Kise Kise Kise 5 (Apoptosis Sigl Regulating Kise 1 or MAPK/ERK Kise Kise 5 or MAP3K5 or EC 2.7.11.25) - Product Development Milestones
Featured News & Press Releases
Nov 08, 2019: PathAI and Gilead show AI-powered pathology research models accurately interpret liver histology in patients with SH at AASLD 2019
Apr 26, 2019: Gilead’s selonsertib fails in second Phase III trial for SH
Apr 11, 2019: Enta Pharmaceuticals to present preclinical data for Non-Alcoholic Steatohepatitis program EP-026856 at ILC 2019
Apr 11, 2019: Enta Pharmaceuticals to present preclinical data for Non-Alcoholic Steatohepatitis program EP-027315 at ILC 2019
Feb 13, 2019: Gilead’s selonsertib fails in Phase III STELLAR-4 study for SH
Nov 09, 2018: Seal Rock Therapeutics advancing differentiated ASK1 inhibitor lead candidate SRT-015 in nolcoholic steatohepatitis (SH)
Nov 09, 2018: Gilead Sciences presents data on Selonsertib at The Liver Meeting 2018
Oct 11, 2018: Gilead to present data on Selonsertib at The Liver Meeting 2018
Apr 13, 2018: Gilead Presents Data on Multiple Investigatiol Regimens for the Treatment of Patients With Nolcoholic Steatohepatitis (SH) and Advanced Fibrosis at The Intertiol Liver Congress 2018
Apr 20, 2017: Gilead to Present Additiol Clinical Data on Selonsertib at The Intertiol Liver Congress 2017
Nov 14, 2016: Phase 2 Data for Selonsertib in Nolcoholic Steatohepatitis Presented at The Liver Meeting 2016
Oct 20, 2016: Gilead Announces Top-Line Phase 2 Results for GS-4997 (Selonsertib) in Nolcoholic Steatohepatitis, Pulmory Arterial Hypertension and Diabetic Kidney Disease
Apr 16, 2016: Gilead Presents New Data on GS-4997 at The Intertiol Liver Congress 2016
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020


List of Tables


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Angion Biomedica Corp, H1 2020
Pipeline by Calchan Ltd, H1 2020
Pipeline by Chipscreen Biosciences Ltd, H1 2020
Pipeline by Enanta Pharmaceuticals Inc, H1 2020
Pipeline by FronThera US Pharmaceuticals LLC, H1 2020
Pipeline by Gilead Sciences Inc, H1 2020
Pipeline by Kyowa Kirin Co Ltd, H1 2020
Pipeline by Seal Rock Therapeutics Inc, H1 2020
Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
Pipeline by Terns Pharmaceuticals Inc, H1 2020
Dormant Projects, H1 2020
Discontinued Products, H1 2020